Literature DB >> 9465547

Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan.

K Wakai1, A Ohta, A Tamakoshi, Y Ohno, T Kawamura, R Aoki, M Kojima, Y Lin, S Hashimoto, Y Inaba, M Minowa, S Aizawa, Y Ichikawa, N Miyasaka.   

Abstract

To estimate prevalence and incidence of adult Still's disease in Japan, and to describe the epidemiological features of the patients, a nationwide epidemiological survey was conducted in 1994. The study consisted of two questionnaires which were distributed to the heads of the relevant departments, randomly sampled, in hospitals throughout Japan. Following major epidemiological findings emerged from the study: (a) The total annual number of patients treated for adult Still's disease was estimated as 1,100 in 1993 in Japan. The estimated crude prevalence among those aged 16 years or older were calculated as 0.73 and 1.47 per 100,000 population for males and females, respectively, with the corresponding crude incidence rate of 0.22 and 0.34. (b) The sex ratio (female to male) of the reported patients was 2.1. This female predominance might be specific to Japan, though additional surveys in other countries will be warranted. The mean age of the patients was 38.1 years, and female patients tended to be older than male ones; 50% of the female patients aged 40 years or older, while so did only 28% of the male patients.

Entities:  

Mesh:

Year:  1997        PMID: 9465547     DOI: 10.2188/jea.7.221

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  45 in total

1.  Therapeutic responses and prognosis in adult-onset Still's disease.

Authors:  Hyoun-Ah Kim; Jun-Mo Sung; Chang-Hee Suh
Journal:  Rheumatol Int       Date:  2011-01-29       Impact factor: 2.631

2.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

Review 3.  [Adult onset Still's disease, fever, diagnosis and therapy].

Authors:  N T Baerlecken; R E Schmidt
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

4.  A rare case of severe acute hepatitis associated with adult-onset still disease dramatically improved by high-dose steroid therapy.

Authors:  Tiffany Hogan; Kevin T Kao; Jim Tung
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

Review 5.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

6.  Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.

Authors:  S Hirata; H Okamoto; S Ohta; T Kobashigawa; M Uesato; Y Kawaguchi; M Tateishi; M Hara; N Kamatani; H-M Tsai
Journal:  Rheumatology (Oxford)       Date:  2006-05-23       Impact factor: 7.580

7.  Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016.

Authors:  Atsushi Masamune; Kazuhiro Kikuta; Shin Hamada; Ichiro Tsuji; Yoshifumi Takeyama; Tooru Shimosegawa; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2019-12-23       Impact factor: 7.527

8.  Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study.

Authors:  Emre Bilgin; Mutlu Hayran; Abdulsamet Erden; Berkan Armağan; Alper Sarı; Levent Kılıç; Ali Akdoğan; Ömer Karadağ; Şule Apraş Bilgen; Sedat Kiraz; İhsan Ertenli; Umut Kalyoncu
Journal:  Clin Rheumatol       Date:  2019-02-01       Impact factor: 2.980

Review 9.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 10.  Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review.

Authors:  Yvan Jamilloux; Alexandre Belot; Flora Magnotti; Sarah Benezech; Mathieu Gerfaud-Valentin; Emilie Bourdonnay; Thierry Walzer; Pascal Sève; Thomas Henry
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.